203 related articles for article (PubMed ID: 26318435)
1. Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behçet uveitis.
Kuroyanagi K; Sakai T; Kohno H; Okano K; Akiyama G; Aoyagi R; Inaba M; Tsuneoka H
Jpn J Ophthalmol; 2015 Nov; 59(6):401-8. PubMed ID: 26318435
[TBL] [Abstract][Full Text] [Related]
2. Human leukocyte antigen B27 and B51 double-positive Behçet uveitis.
Ahn JK; Park YG
Arch Ophthalmol; 2007 Oct; 125(10):1375-80. PubMed ID: 17923546
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.
Keino H; Okada AA; Watanabe T; Nakayama M; Nakamura T
Ocul Immunol Inflamm; 2017 Feb; 25(1):46-51. PubMed ID: 27767359
[TBL] [Abstract][Full Text] [Related]
4. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.
Sakai T; Watanabe H; Kuroyanagi K; Akiyama G; Okano K; Kohno H; Tsuneoka H
Br J Ophthalmol; 2013 Mar; 97(3):338-42. PubMed ID: 23314623
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Behçet disease.
Umazume A; Kezuka T; Usui Y; Suzuki J; Goto H
Jpn J Ophthalmol; 2018 May; 62(3):390-397. PubMed ID: 29582190
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
7. Genetic and non-genetic factors affecting the visual outcome of ocular Behcet's disease.
Kang EH; Park JW; Park C; Yu HG; Lee EB; Park MH; Song YW
Hum Immunol; 2013 Oct; 74(10):1363-7. PubMed ID: 23831258
[TBL] [Abstract][Full Text] [Related]
8. HLA-A26 is a risk factor for Behçet's disease ocular lesions.
Kato H; Takeuchi M; Horita N; Ishido T; Mizuki R; Kawagoe T; Shibuya E; Yuda K; Ishido M; Mizuki Y; Hayashi T; Meguro A; Kirino Y; Minegishi K; Nakano H; Yoshimi R; Kurosawa M; Fukumoto T; Takeno M; Hotta K; Kaneko T; Mizuki N
Mod Rheumatol; 2021 Jan; 31(1):214-218. PubMed ID: 31851572
[TBL] [Abstract][Full Text] [Related]
9. Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab.
Kaburaki T; Namba K; Sonoda KH; Kezuka T; Keino H; Fukuhara T; Kamoi K; Nakai K; Mizuki N; Ohguro N;
Jpn J Ophthalmol; 2014 Mar; 58(2):120-30. PubMed ID: 24482146
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Treatment Results for Behçet Uveitis in Patients Treated with Infliximab and Interferon.
Yalçindag N; Köse HC
Ocul Immunol Inflamm; 2020; 28(2):305-314. PubMed ID: 31268743
[No Abstract] [Full Text] [Related]
11. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease.
Okada AA; Goto H; Ohno S; Mochizuki M;
Arch Ophthalmol; 2012 May; 130(5):592-8. PubMed ID: 22652845
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
Yamana S; Hasegawa E; Takeda A; Yawata N; Sonoda KH
Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
[TBL] [Abstract][Full Text] [Related]
13. Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Sota J; Vannozzi L; di Scala G; Guerriero S; Orlando I; Franceschini R; Capozzoli M; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2018 Jun; 37(6):1715-1720. PubMed ID: 29671190
[TBL] [Abstract][Full Text] [Related]
14. Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy.
Köse HC; Yalçındağ N
Ocul Immunol Inflamm; 2022 Jan; 30(1):203-207. PubMed ID: 32779960
[TBL] [Abstract][Full Text] [Related]
15. HLA-B51 and its allelic types in association with Behçet's disease and recurrent aphthous stomatitis in Korea.
Chang HK; Kim JU; Cheon KS; Chung HR; Lee KW; Lee IH
Clin Exp Rheumatol; 2001; 19(5 Suppl 24):S31-5. PubMed ID: 11760395
[TBL] [Abstract][Full Text] [Related]
16. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M
Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505
[TBL] [Abstract][Full Text] [Related]
17. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
Tabbara KF; Al-Hemidan AI
Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease.
Giansanti F; Barbera ML; Virgili G; Pieri B; Emmi L; Menchini U
Eur J Ophthalmol; 2004; 14(5):445-8. PubMed ID: 15506610
[TBL] [Abstract][Full Text] [Related]
19. Successful Treatment with Infliximab for Refractory Uveitis in a Hemodialysis Patient with Behçet's Disease and a Review of the Literature for Infliximab Use in Patients on Hemodialysis.
Kurata I; Tsuboi H; Takahashi H; Abe S; Ebe H; Hagiwara S; Umeda N; Kondo Y; Ogishima H; Suzuki T; Matsumoto I; Hoshi S; Oshika T; Sumida T
Intern Med; 2015; 54(12):1553-7. PubMed ID: 26073249
[TBL] [Abstract][Full Text] [Related]
20. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
